Weight ManagementAlso known as: ALT-801, GLP-1/glucagon dual agonist

Pemvidutide

Pemvidutide is a highly specialized, clinical-grade dual GLP-1/Glucagon agonist expressly built to target and exterminate liver fat. While it drives massive systemic weight loss (15%+), its crown jewel is its unmatched ability to aggressively resolve MASH (steatohepatitis) and NAFLD by rapidly stripping severe lipid accumulations directly out of the hepatic tissue, saving failing livers.

Reviewed by CalcMyPeptide Editorial Team

·Last updated: April 2026·Evidence: Emerging·1 peer-reviewed citation

Quick Stats

Half-Life~7 days (once weekly)

Dose Range1.2-2.4 mg/week

Frequency1× weekly

Vial Sizes2.4 mg

Bioavailability~85% (SC estimated)

Year Developed2022

Scientific Data

Molecular Formula

Dual GLP-1/GCGr peptide analog

Molecular Weight

~4200 Da

Developer

Altimmune Inc.

Mechanism of Action

Pemvidutide (ALT-801) is a balanced GLP-1/glucagon dual receptor agonist developed by Altimmune. Its differentiating design: balanced 1:1 GLP-1:GCGr activity ratio, which maximises energy expenditure (via glucagon) while maintaining appetite suppression (via GLP-1). Phase 2 MOMENTUM trial showed 15.6% body weight reduction at 2.4 mg over 48 weeks — with notably superior muscle mass preservation vs semaglutide alone (lean mass loss was 22% lower). This muscle-sparing profile makes it particularly relevant for body composition optimization.

Source: PMID: 37578887 (MOMENTUM Phase 2)

Dosing Protocol

Typical Dose	1.2-2.4 mg/week
Frequency	1× weekly
Half-Life	~6-7 days
Common Vial Sizes	2.4 mg

Dosing Protocols

Phase 2 Protocol

Dose

1.2 mg / 1.8 mg / 2.4 mg

Frequency

Once weekly (SC)

Note: Escalating dose over 12 weeks then maintenance. Phase 3 ongoing.

Administration

Route

Subcutaneous injection

Timing

Once weekly, same day.

Fasting Required?

No — food timing not critical

Expected Timeline

Month 1-3

Rapid weight loss onset. Glucagon receptor activity drives higher energy expenditure vs GLP-1 alone.

Month 6-12

15.6% body weight reduction at 2.4 mg (MOMENTUM Phase 2, 48 weeks).

Who Is It For?

Obesity with Muscle Preservation Priority

High

Key differentiator: 22% lower lean mass loss vs semaglutide. Ideal for body composition goals.

Metabolic Liver Disease (MASH)

Emerging

Strong hepatic fat reduction signal via glucagon receptor activation.

Reconstitution Example

Vial

2.4 mg

Water

1 mL

Concentration

2.4 mg/mL

Per Unit (100u syringe)

24 mcg

Dose of 1200 mcg = 50 units on a 100-unit insulin syringe

🧮 Calculate Your Exact Pemvidutide Dose →

Safety & Considerations

Investigational — not FDA-approved. Phase 3 ongoing. GI profile consistent with GLP-1 class. Muscle preservation advantage may be clinically meaningful for active patients and older adults.

Regulatory & Legal Status

FDA Status (US)

Research Only

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Dosing Quick Reference

Pemvidutide— Dosing Guide

Dose Range

1.2-2.4 mg/week

Half-Life

~6-7 days

Frequency

1× weekly

Route

Subcutaneous

2.4 mg vial

💧 1 mL BAC water|📐 2.4 mg/mL concentration|💉 24 mcg/unit (100u syringe)

Weight Managementcalcmypeptide.com

Frequently Asked Questions

Why does pemvidutide preserve muscle better than semaglutide?▼

Pemvidutide's balanced glucagon receptor agonism increases fatty acid oxidation and metabolic rate, reducing reliance on muscle catabolism for energy. GLP-1-only agents like semaglutide lose more lean mass as part of total weight loss.

Is pemvidutide FDA-approved?▼

No. Phase 3 trials are ongoing following successful Phase 2 MOMENTUM results. FDA filing expected 2026-2027.

References

Altimmune Inc. (MOMENTUM Phase 2 data) “"Pemvidutide (ALT-801) Phase 2 MOMENTUM trial results".” Obesity Week / Press Release (2024).

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide

14 min read • Pillar Guide

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library